CHICAGO , June 17, 2022 /PRNewswire/ -- According to the new market research report "Nucleic Acid Isolation and Purification Market by Product (Kit, Reagent, Instrument), Method (Column, Magnetic Beads), Type (Genomic DNA, Plasmid DNA, miRNA), Application (Drug Discovery, Diagnostics), End User (Pharma, Biotech) – Global Forecast to 2027", published by MarketsandMarkets™, the global Nucleic Acid Isolation and Purification Market is projected to reach USD 9.2 billion by 2027 from USD 6.3 billion in 2022, at a CAGR of 7.9% during the forecast period.
Browse in-depth TOC on "Nucleic Acid Isolation & Purification Market" 173 – Tables 36 – Figures 237 – Pages
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=229978287
The growth of this market can mainly be attributed to the increasing R&D activities as well as technological advancements and increasing automation. The emerging economies and improving regulatory & reimbursement scenario are expected to offer a wide range of growth opportunities for players in the nucleic acid purification market.
Due to the COVID-19 outbreak, there has been a significant increase in testing and drug research pertaining to the disease. The research in this area is being furthered to better understand the dynamics of the infection, which is expected to propel the nucleic acid isolation and purification field further. On the other hand, it is estimated that the major share of diagnostic assays and molecular testing of COVID-19, along with personalized medicine, will grow at a stable pace in the next five years. There is a huge increase of manufacturers that have taken key steps to increase patient access to coronavirus diagnostic testing and vaccine and drug development in laboratories, hospitals, and other testing sites across the country to guide patient care and protect public health.
Due to the rapid spread of the coronavirus, the demand for diagnostic kits and other critical care medical devices has witnessed exponential growth in the last two years. In 2020–2021, healthcare provider facilities across the globe were overwhelmed with patient submissions for COVID-19 screening & treatment. This resulted in severe disruptions in clinical workflows within inpatient care facilities, leading to the prioritization of critical patient care procedures by provider facilities.
By product, the kits segment accounted for the largest market share in 2021.
On the basis of product, the nucleic acid isolation market has been segmented into kits, reagents, and instruments. The kits segment accounted for the largest share of the global nucleic acid purification market in 2021. Growth in this market can be attributed to the increasing demand for kits and reagents for DNA and RNA isolation during research studies carried out to understand genetic abnormalities.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=229978287
By application, the diagnostics segment is expected to grow at the highest CAGR during the forecast period.
On the basis of application, the global nucleic acid isolation and purification market is segmented into diagnostics, drug discovery & development, personalized medicine, agriculture & animal research, and other applications. The diagnostics segment is expected to grow at the highest CAGR during the forecast period. The high growth rate of this segment can be attributed to the growing awareness of genomic diagnostics among patients and the increasing efficiency of genomics sequencing in the diagnosis of diseases. Also, the increasing use of DNA and RNA isolation for screening and detecting pathogens and microorganism in routine samples and rapid adoption of PCR techniques to detect genetic abnormalities is expected to drive the segment growth.
By Type, the plasmid DNA isolation and purification segment accounted for the largest market share in 2021. On the basis of type, the global nucleic acid isolation and purification market is segmented into plasmid DNA isolation and purification, total RNA isolation and purification, circulating nucleic acid isolation and purification, genomic DNA isolation and purification, messenger RNA isolation and purification, microRNA isolation and purification, PCR cleanup, and other nucleic acid isolation and purification types. In 2021, the plasmid DNA isolation segment accounted for the largest share of the market. The large share of this market segment can be attributed to the wide use of purified plasmid DNA in a variety of downstream applications, such as PCR, sequencing, expression of proteins, gene therapy, and transfection. Moreover, the availability of a broad range of kits for extraction and processing of plasmid DNA, and the increasing application in gene expression profiling is further contributing to segment growth.
Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=229978287
North America dominates the nucleic acid isolation and purification market during the forecast period.
In 2021, North America accounted for the largest share of the nucleic acid purification market, followed by Europe . The large share of this region can be attributed to factors such as significant R&D spending in biotechnology and pharmaceutical companies, the large size of the biotechnology industry, technological advancements, and government support in the region. With rapid development in molecular biotechnology, novel detection techniques and molecular diagnostic represented by nucleic acid hybridization and nucleic acid sequence analysis are becoming increasingly significant in various medical fields. Hence, leading players in the market are focusing on entering into a strategic collaboration to develop novel products. For instance, in Market 2020, Zymo Research announced entering into collaboration with, a laboratory instruments and solutions provider, Tecan to launch ready-to-use processing products for streamlining DNA and RNA extraction for nucleic acid hybridization. Such product launches are expected to facilitate the growth in the North American region. However, the Asia Pacific region is expected to grow at the highest rate during the forecast period
The prominent players in this nucleic acid isolation market are QIAGEN N.V. (Netherlands ), Thermo Fisher Scientific (US), F. Hoffmann-La Roche Ltd. (Switzerland ), Merck KGaA (Germany ), Bio-Rad Laboratories (US), Agilent Technologies (US), Danaher Corporation (US), GE Healthcare (US), Illumina, Inc. (US), Takara Bio (Japan ), Zymo Research (US), New England Biolabs (US), Norgen Biotek Corp (Canada ), and Omega Bio -tek (US).
Browse Adjacent Markets: Biotechnology Market Research Reports & Consulting
Cell Lysis & Cell Fractionation Market by Product (Consumables (Enzymes, Detergent), Instruments (Sonicators)), Cell Type (Mammalian), Application (Protein Purification), End User (Biopharmaceutical & Biotechnology Companies) - Global Forecast to (2022 - 2026) https://www.marketsandmarkets.com/Market-Reports/cell-lysis-market-260138321.html
Molecular Biology Enzymes & Kits & Reagents Market by Product (Kit, Reagent, Enzyme), Application (PCR, Sequencing, Epigenetic, Synthetic Biology), End user (Research Institutes, Pharma & Biotech Company, Hospitals) and Region - Global Forecast to 2026 https://www.marketsandmarkets.com/Market-Reports/molecular-biology-enzymes-kits-reagents-market-164131709.html
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact: Mr. Aashish Mehra MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA : +1-888-600-6441 Email: sales@marketsandmarkets.com Research Insight: https://www.marketsandmarkets.com/ResearchInsight/nucleic-acid-isolation-purification-market.asp Visit Our Web Site: https://www.marketsandmarkets.com Content Source: https://www.marketsandmarkets.com/PressReleases/nucleic-acid-isolation-purification.asp
Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/nucleic-acid-isolation-and-purification-market-worth-9-2-billion-by-2027--exclusive-report-by-marketsandmarkets-301570251.html
Will Solutions (Will) is proud to announce that it will be joining the Microsoft for Startups Program. This will enable Will to accelerate the deployment of its digital solutions using Microsoft Azure, and subsequently integrating with the Microsoft Cloud for Sustainability.
Anyone positioning their portfolio for a recession could be making a big mistake.
While not strictly speaking an evangelist, billionaire Mark Cuban has invested in the industry. "In stocks and crypto, you will see companies that were sustained by cheap, easy money—but didn't have valid business prospects—will disappear," Cuban said. The most popular cryptocurrency is currently trading at around $20,657.77, according to data firm CoinGecko.
When Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) CEO Warren Buffett speaks, Wall Street and investors wisely pay close attention. While riding Buffett's coattails has been a moneymaking strategy for decades, it's equally important to take note of the stocks that the world's most successful investor and his investing team are selling or avoiding. Thus far in 2022, Warren Buffett has overseen the aggressive selling of the following five stocks.
Investors might take some comfort in crystal-ball gazing by Bank of America, which uses history to plot the next bull market.
Already, very early signs of slowing demand and inflation are cropping up. If the economy averts all-out disaster, then stabilizing or declining rates would spur a market rebound.
‘Bitcoin has already broken down [and is] now seeing significant downside follow-through,’ says Katie Stockton of Fairlead Strategies. Bitcoin believer Yves Lamoureux of Lamoureux & Co., though, thinks ‘bitcoin is fine.’
AMD and Nvidia have been swallowed up in the bear market, with each stock declining at least 50%. Here's how to trade them now.
Retail stocks have taken a beating, but inflation, supply chain woes, and other cost concerns don't tell the full story.
Since hitting their all-time closing highs, the widely followed Dow Jones Industrial Average, benchmark S&P 500, and growth stock-fueled Nasdaq Composite (NASDAQINDEX: ^IXIC) have respectively tumbled by 17%, 22%, and 33%. There's no question that the velocity and unpredictability of downward moves during a bear market can weigh on investors' psyche. This makes corrections and bear markets the opportune time to put your money to work.
Remember TINA? She’s the one everyone was talking about for the past few years, when it came to buying stocks. ‘There is no alternative,’ they said – pointing out that the near-zero interest rate policy has pushed bond yields down to nothing, and that the housing crisis of 2008 had left investors wary of the real estate market – and stocks were the highest returning game in town. Not anymore. The Federal Reserve has just cracked the whip on rate hikes, implementing a 0.75% increase to the benchm
A decline in earnings could be the next shoe to drop for investors. But it’s all a prelude to what may be the best buying opportunity in decades.
Bank stocks are dirt-cheap right now, and Citi in particular looks like a bargain. Watch the Fed’s stress-test results—and Warren Buffett’s purchases—to see what might be in store.
This year’s plunge in the stock market, unprecedented crash in the bond market, and surging inflation threaten new retirees in ways not seen before, he says. “The Jan. 1, 2022 retiree is retiring under conditions which have no certain precedent in the historical records I have used for my research,” Bengen tells MarketWatch. If the recent surge in inflation isn’t brought under control, he says, “we may witness history being made, and the first decline in the ‘safe’ withdrawal rate in more than 50 years.”
The major indexes sold off on recession fears, while Bitcoin broke another key level. Tesla rival BYD is near a buy point.
Stocks' stomach-churning start to 2022 raises big questions for the next six months. Here's what you should know.
The cryptocurrency industry was built on swagger, enthusiasm and optimism. All three are in short supply these days, as losses and layoffs mount.
Credit Suisse has warned of a “new world order” in financial markets after central banks began aggressively ramping up interest rates.
(Bloomberg) -- For all the talk of bear markets and a possible recession, investors continue to pile into American equities.Most Read from BloombergChina Says It May Have Detected Signals From Alien CivilizationsMusk, Tesla, SpaceX Are Sued for Alleged Dogecoin Pyramid Scheme'Drip Pricing' Is Turning Checkout Into a Nasty SurpriseTech Leads Gains as Traders Parse Fed’s Promise: Markets WrapBiden Signals US Can Avert Recession But Americans Are ‘Really Down’US stocks attracted $14.8 billion in th
Don't let its share price movement fool you. This e-commerce stock is poised to bounce back in the long run.